Genentech's Investment Community Meeting presentation contains forward-looking statements regarding being the number one U.S. oncology company in sales, growth in non-GAAP earnings per share (EPS), operating revenues and cumulative free cash flow, adding new molecular entities into development, and major new product or indication approvals; enrolling patients for or initiating clinical studies of Systemic Hedgehog Antagonist, Anti-CD40 molecule, Avastin, 2nd Generation Anti-CD20 and other new molecular entities; availability of data or completion of data analysis for clinical studies for Avastin, Trastuzumab-DM1, Avastin +/- Apomab, Avastin + Herceptin, Apo2L/TRAIL +/- Avastin, Rituxan, Pertuzumab, Tarceva, Herceptin, Systemic Hedgehog Antagonist, 2nd Generation anti-CD20 molecule, 3rd Generation anti-CD20 molecule, ABT-263, ABT-869, Anti- CD40 molecule, Xolair, Lucentis and Anti-OX40L; submitting a BLA for Avastin; the potential of combination therapies; potential label expansions for Avastin, Avastin + Tarceva, Herceptin, Rituxan, Tarceva, Xolair, Lucentis, Nutropin and TNKase; Avastin, Herceptin, Xolair and Rituxan growth potential; product launches and growth from such launches; Rituxan safety and efficacy; marketing and sales expenditures; and manufacturing approvals. These forward-looking statements are predictions and involve risks and uncertainties that could cause actual results to differ materially from those predicted in any such forward-looking statements. Such risks and uncertainties include, but are not limited to, difficulty in enrolling patients in clinical trials; the need for additional data, data analysis or clinical studies; the results of clinical trials; BLA preparation and decision making; FDA actions or delays; failure to obtain or maintain FDA approval; difficulty in obtaining materials from suppliers; unexpected safety, efficacy or manufacturing issues for us or our contract/collaborator manufacturers; our ability to meet demand for our products; product withdrawals; competition; efficacy data concerning any of our products which shows or is perceived to show similar or improved treatment benefit at a lower dose or shorter duration of therapy; pricing decisions by us or our competitors; our ability to protect our proprietary rights; the outcome of, and expenses associated with, litigation or legal settlements; our cost of sales, other expenses and indebtedness; variations in collaborator sales and expenses; fluctuations in contract revenues and royalties; actions by Roche that are adverse to our interests; decreases in third party reimbursement rates; and changes in tax laws or the application or interpretation of such laws. Please also refer to Genentech's periodic reports filed with the Securities and Exchange Commission. We disclaim and do not undertake any obligation to update or revise any forward-looking statement in this presentation.

I have read the above and wish to access the presentation/webcast materials.